TWI906204B - 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 - Google Patents
用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法Info
- Publication number
- TWI906204B TWI906204B TW108144617A TW108144617A TWI906204B TW I906204 B TWI906204 B TW I906204B TW 108144617 A TW108144617 A TW 108144617A TW 108144617 A TW108144617 A TW 108144617A TW I906204 B TWI906204 B TW I906204B
- Authority
- TW
- Taiwan
- Prior art keywords
- dose
- antisense oligonucleotide
- administered
- pharmaceutical composition
- loading
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779916P | 2018-12-14 | 2018-12-14 | |
| US62/779,916 | 2018-12-14 | ||
| US201962807603P | 2019-02-19 | 2019-02-19 | |
| US62/807,603 | 2019-02-19 | ||
| US201962840879P | 2019-04-30 | 2019-04-30 | |
| US62/840,879 | 2019-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202035694A TW202035694A (zh) | 2020-10-01 |
| TWI906204B true TWI906204B (zh) | 2025-12-01 |
Family
ID=69160351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108144617A TWI906204B (zh) | 2018-12-14 | 2019-12-06 | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220073930A1 (https=) |
| EP (1) | EP3894557A1 (https=) |
| JP (2) | JP7612575B2 (https=) |
| KR (2) | KR20250090384A (https=) |
| CN (3) | CN118987017A (https=) |
| AU (1) | AU2019396522B2 (https=) |
| BR (1) | BR112021011334A2 (https=) |
| CA (1) | CA3115549A1 (https=) |
| CL (1) | CL2021001136A1 (https=) |
| CO (1) | CO2021008187A2 (https=) |
| CR (1) | CR20210384A (https=) |
| IL (1) | IL283833A (https=) |
| JO (1) | JOP20210143A1 (https=) |
| MX (1) | MX2021005086A (https=) |
| MY (1) | MY209775A (https=) |
| PH (1) | PH12021551365A1 (https=) |
| SG (1) | SG11202103415WA (https=) |
| TW (1) | TWI906204B (https=) |
| UY (1) | UY38506A (https=) |
| WO (1) | WO2020123783A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| CN119679944A (zh) | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| BR112023019877A2 (pt) * | 2021-03-31 | 2023-11-07 | Biogen Ma Inc | Tratamento de esclerose lateral amiotrófica |
| WO2025045130A1 (zh) * | 2023-08-29 | 2025-03-06 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制sod1基因表达的dsrna分子及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153800A2 (en) * | 2014-04-01 | 2015-10-08 | Isis Pharmaceuticals, Inc. | Compositions for modulating sod-1 expression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
| EP3119888B1 (en) * | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
| WO2016077687A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP2020518258A (ja) * | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| WO2018218219A1 (en) * | 2017-05-26 | 2018-11-29 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
-
2019
- 2019-12-06 TW TW108144617A patent/TWI906204B/zh active
- 2019-12-11 UY UY0001038506A patent/UY38506A/es not_active Application Discontinuation
- 2019-12-12 JP JP2021525191A patent/JP7612575B2/ja active Active
- 2019-12-12 EP EP19836331.9A patent/EP3894557A1/en active Pending
- 2019-12-12 MX MX2021005086A patent/MX2021005086A/es unknown
- 2019-12-12 CR CR20210384A patent/CR20210384A/es unknown
- 2019-12-12 CA CA3115549A patent/CA3115549A1/en active Pending
- 2019-12-12 MY MYPI2021003225A patent/MY209775A/en unknown
- 2019-12-12 CN CN202411184883.6A patent/CN118987017A/zh active Pending
- 2019-12-12 SG SG11202103415WA patent/SG11202103415WA/en unknown
- 2019-12-12 KR KR1020257019188A patent/KR20250090384A/ko active Pending
- 2019-12-12 US US17/291,199 patent/US20220073930A1/en active Pending
- 2019-12-12 AU AU2019396522A patent/AU2019396522B2/en active Active
- 2019-12-12 WO PCT/US2019/065936 patent/WO2020123783A1/en not_active Ceased
- 2019-12-12 KR KR1020217020529A patent/KR102821047B1/ko active Active
- 2019-12-12 CN CN201980080996.2A patent/CN113330116A/zh active Pending
- 2019-12-12 CN CN202411184930.7A patent/CN119185345A/zh active Pending
- 2019-12-12 BR BR112021011334-7A patent/BR112021011334A2/pt unknown
-
2021
- 2021-04-29 CL CL2021001136A patent/CL2021001136A1/es unknown
- 2021-06-09 IL IL283833A patent/IL283833A/en unknown
- 2021-06-09 PH PH12021551365A patent/PH12021551365A1/en unknown
- 2021-06-09 JO JOP/2021/0143A patent/JOP20210143A1/ar unknown
- 2021-06-23 CO CONC2021/0008187A patent/CO2021008187A2/es unknown
-
2024
- 2024-12-06 JP JP2024213950A patent/JP2025023319A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153800A2 (en) * | 2014-04-01 | 2015-10-08 | Isis Pharmaceuticals, Inc. | Compositions for modulating sod-1 expression |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220073930A1 (en) | 2022-03-10 |
| KR20210131992A (ko) | 2021-11-03 |
| MX2021005086A (es) | 2021-08-16 |
| KR20250090384A (ko) | 2025-06-19 |
| EP3894557A1 (en) | 2021-10-20 |
| JOP20210143A1 (ar) | 2023-01-30 |
| CN118987017A (zh) | 2024-11-22 |
| UY38506A (es) | 2020-06-30 |
| CN113330116A (zh) | 2021-08-31 |
| JP7612575B2 (ja) | 2025-01-14 |
| TW202035694A (zh) | 2020-10-01 |
| BR112021011334A2 (pt) | 2021-09-08 |
| CA3115549A1 (en) | 2020-06-18 |
| MY209775A (en) | 2025-08-03 |
| CN119185345A (zh) | 2024-12-27 |
| KR102821047B1 (ko) | 2025-06-16 |
| CL2021001136A1 (es) | 2022-01-14 |
| AU2019396522B2 (en) | 2026-04-09 |
| JP2022513597A (ja) | 2022-02-09 |
| CR20210384A (es) | 2021-12-20 |
| SG11202103415WA (en) | 2021-06-29 |
| IL283833A (en) | 2021-07-29 |
| CO2021008187A2 (es) | 2021-09-09 |
| JP2025023319A (ja) | 2025-02-14 |
| WO2020123783A1 (en) | 2020-06-18 |
| PH12021551365A1 (en) | 2021-11-22 |
| AU2019396522A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI906204B (zh) | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 | |
| JP6637121B2 (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| US7622455B2 (en) | Methods for slowing familial ALS disease progression | |
| KR102941589B1 (ko) | 프리온 발현을 감소시키기 위한 화합물 및 방법 | |
| CN106459972A (zh) | 用于调节sod‑1表达的组合物 | |
| KR20210008498A (ko) | Fxi 발현을 감소시키기 위한 화합물 및 방법 | |
| JP2025100729A (ja) | 補体成分３の発現を阻害するための組成物及び方法 | |
| KR20210102294A (ko) | 근위축성 측삭 경화증에서 치료요법적 중재를 안내하기 위한 신경필라멘트 단백질 | |
| RU2824046C2 (ru) | Составы для лечения и предотвращения бокового амиотрофического склероза | |
| JP2024511767A (ja) | 筋萎縮性側索硬化症の治療 | |
| EA051069B1 (ru) | Составы и способы лечения и предотвращения бокового амиотрофического склероза | |
| RU2793459C2 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| RU2858547C2 (ru) | Композиции для модулирования экспрессии sod-1 | |
| CN120359038A (zh) | 抑制性核酸及其使用方法 | |
| CN121358862A (zh) | 用于治疗肾脏疾病的组合物和方法 |